Johann Philipp Zöllner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Johann Philipp Zöllner has a total of 161 co-authors. Here are the top co-authors by number of shared publications:
Felix Rosenow
Department of Neurology and Epilepsy Center Frankfurt Rhine‐Main, Goethe‐University Frankfurt University Hospital Frankfurt Frankfurt am Main Germany
28 shared publications- Adam Strzelczyk
Epilepsy Center Frankfurt Rhine‐Main, Department of Neurology Goethe‐University Frankfurt Frankfurt am Main Germany
27 shared publications - Laurent Maximilian Willems
Epilepsy Center Frankfurt Rhine-Main, Department of Neurology, Goethe-University and University Medical Center Frankfurt, Theodor-Stern-Kai 7 (Haus 23D), 60596, Frankfurt am Main, Germany.
12 shared publications Adam Strzelczyk
Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, University Hospital, Goethe University, Frankfurt am Main, Germany
10 shared publications- Felix Rosenow
Department of Neurology, Epilepsy Center Frankfurt Rhine-Main, Goethe University Frankfurt, Frankfurt am Main, Germany
7 shared publications Philipp S. Reif
Epilepsy Center Frankfurt Rhine-Main, Center of Neurology and Neurosurgery, Goethe-University Frankfurt, University Hospital Frankfurt, Schleusenweg 2-16, Haus 95, 60528, Frankfurt am Main, Germany
6 shared publications
Latest Publications
- Open Access
- 23 January 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 136, 31-39
Clinical reliability and concordance of drug-drug interaction tools as clinical decision support systems in patients with epilepsy
- 23 January 2026
- Published by Elsevier in Seizure: European Journal of Epilepsy
- Vol. 136, 31-39
Open AccessClinical reliability and concordance of drug-drug interaction tools as clinical decision support systems in patients with epilepsy
- Open Access
Sleep quality and its correlates in people with epilepsy: A multicenter cross‐sectional study in Germany
Objective: Sleep disturbances and epilepsy are closely interrelated. This study aimed to examine associations between sleep quality, affective symptoms, and quality of life (QoL) in people with epilepsy (PWE), and to identify clinical and sociodemographic factors linked to impaired sleep. Methods: We conducted a multicenter cross‐sectional study of adult PWE across four tertiary epilepsy centers in Germany. We assessed sleep quality using the Pittsburgh Sleep Quality Index (PSQI), affective symptoms with the Hospital Anxiety and Depression Scale (HADS), and epilepsy‐specific QoL with the 31‐item Quality of Life in Epilepsy (QOLIE‐31) inventory. We evaluated sociodemographic and clinical predictors of sleep quality and QoL using univariable and multivariable analyses. Comparisons were made with normative data from the general German population and individuals with chronic migraine. Results: Of 449 individuals (mean age 39.9 years, 58.1% women), 221 (49.2%) were identified as “poor sleepers,” significantly exceeding rates in the general population (35.9%, p < .001). In multivariable analysis, poor sleep quality was independently associated with female sex (odds ratio [OR] 2.02, 95% confidence interval [CI] 1.36–3.01, p = .001), unemployment (OR 1.74, 95% CI = 1.10–2.73, p = .017), anxiety (OR = 3.79, 95% CI = 2.39–6.04, p < .001), and depression (OR = 2.19, 95% CI = 1.36–3.54, p = .001). In addition, daily seizures were linked to worse sleep quality (OR = 2.55, 95% CI = 1.03–6.30, p = .042). Poor sleep was independently associated with lower epilepsy‐related QoL after adjusting for affective symptoms and seizure frequency (OR = 1.79, 95% CI = 1.20–2.68, p = .005). Significance: Sleep quality in PWE is significantly impaired and strongly associated with anxiety, depression, and sociodemographic variables in addition to epilepsy‐specific factors. Poor sleep independently correlates with diminished QoL, supporting the value of routine screening for affective symptoms and sleep disturbances in epilepsy care.
Open AccessSleep quality and its correlates in people with epilepsy: A multicenter cross‐sectional study in Germany
Objective: Sleep disturbances and epilepsy are closely interrelated. This study aimed to examine associations between sleep quality, affective symptoms, and quality of life (QoL) in people with epilepsy (PWE), and to identify clinical and sociodemographic factors linked to impaired sleep. Methods: We conducted a multicenter cross‐sectional study of adult PWE across four tertiary epilepsy centers in Germany. We assessed sleep quality using the Pittsburgh Sleep Quality Index (PSQI), affective symptoms with the Hospital Anxiety and Depression Scale (HADS), and epilepsy‐specific QoL with the 31‐item Quality of Life in Epilepsy (QOLIE‐31) inventory. We evaluated sociodemographic and clinical predictors of sleep quality and QoL using univariable and multivariable analyses. Comparisons were made with normative data from the general German population and individuals with chronic migraine. Results: Of 449 individuals (mean age 39.9 years, 58.1% women), 221 (49.2%) were identified as “poor sleepers,” significantly exceeding rates in the general population (35.9%, p < .001). In multivariable analysis, poor sleep quality was independently associated with female sex (odds ratio [OR] 2.02, 95% confidence interval [CI] 1.36–3.01, p = .001), unemployment (OR 1.74, 95% CI = 1.10–2.73, p = .017), anxiety (OR = 3.79, 95% CI = 2.39–6.04, p < .001), and depression (OR = 2.19, 95% CI = 1.36–3.54, p = .001). In addition, daily seizures were linked to worse sleep quality (OR = 2.55, 95% CI = 1.03–6.30, p = .042). Poor sleep was independently associated with lower epilepsy‐related QoL after adjusting for affective symptoms and seizure frequency (OR = 1.79, 95% CI = 1.20–2.68, p = .005). Significance: Sleep quality in PWE is significantly impaired and strongly associated with anxiety, depression, and sociodemographic variables in addition to epilepsy‐specific factors. Poor sleep independently correlates with diminished QoL, supporting the value of routine screening for affective symptoms and sleep disturbances in epilepsy care.
- Open Access
- 27 May 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (6) , e70225
Clinical Findings in Temporal Lobe Epilepsy Associated With Isolated Amygdala Enlargement
Background: Mesial temporal lobe epilepsy (mTLE) infrequently presents with isolated amygdala enlargement (AE), but its relevance remains ambiguous. We therefore investigated clinical, imaging, and histopathological findings in mTLE‐AE compared to non‐lesional mTLE (mTLE‐NL) patients, and additionally strategies for identifying AE.Methods: We detected AE by automated volumetry of otherwise unremarkable magnetic resonance images of mTLE patients, compared with a healthy comparator. Autoimmune inflammation as an AE cause was excluded using the Graus criteria. We compared clinical and neuropsychological variables between mTLE‐AE and mTLE‐NL. Secondary assessment of AE was by neuroradiologist visual detection.Results: Of 63 mTLE patients, 15 had mTLE‐AE. In these, normalized mean volume was 1857.58 mm3 (SD = 207.38) for the left, 1973.09 mm3 (SD = 214.91) for the right amygdala, 2003.34 mm3 (SD = 218.85) for the larger and 1827.34 mm3 (SD = 179.85) for the smaller amygdala. Mean volume in the healthy control subjects was 1853.4 mm3 for the left (SD = 212.44) and 1895.2 mm3 for the right amygdala (SD = 224.29). Clinical parameters including age, sex, epilepsy duration, history of febrile convulsions, drug resistance, neuropsychological performance, surgical outcome, and medications did not differ significantly between mTLE‐AE and mTLE‐NL. Histopathological findings in mTLE‐AE included dysmorphic neurons, potential tumors, and focal cortical dysplasia. Neuroradiologists independently described AE in 37 of 63 mTLE patients.Conclusions: mTLE‐AE has no specific clinical profile compared to non‐lesional mTLE and features diverse underlying pathologies. Volumetric detection appears more conservative than conventional qualitative visual analysis, but may miss cases of subtle AE. Combining automated volumetry with visual assessment may improve AE detection.
- 27 May 2025
- Published by Wiley in European Journal of Neurology
- Vol. 32 (6) , e70225
Open AccessClinical Findings in Temporal Lobe Epilepsy Associated With Isolated Amygdala Enlargement
Background: Mesial temporal lobe epilepsy (mTLE) infrequently presents with isolated amygdala enlargement (AE), but its relevance remains ambiguous. We therefore investigated clinical, imaging, and histopathological findings in mTLE‐AE compared to non‐lesional mTLE (mTLE‐NL) patients, and additionally strategies for identifying AE.Methods: We detected AE by automated volumetry of otherwise unremarkable magnetic resonance images of mTLE patients, compared with a healthy comparator. Autoimmune inflammation as an AE cause was excluded using the Graus criteria. We compared clinical and neuropsychological variables between mTLE‐AE and mTLE‐NL. Secondary assessment of AE was by neuroradiologist visual detection.Results: Of 63 mTLE patients, 15 had mTLE‐AE. In these, normalized mean volume was 1857.58 mm3 (SD = 207.38) for the left, 1973.09 mm3 (SD = 214.91) for the right amygdala, 2003.34 mm3 (SD = 218.85) for the larger and 1827.34 mm3 (SD = 179.85) for the smaller amygdala. Mean volume in the healthy control subjects was 1853.4 mm3 for the left (SD = 212.44) and 1895.2 mm3 for the right amygdala (SD = 224.29). Clinical parameters including age, sex, epilepsy duration, history of febrile convulsions, drug resistance, neuropsychological performance, surgical outcome, and medications did not differ significantly between mTLE‐AE and mTLE‐NL. Histopathological findings in mTLE‐AE included dysmorphic neurons, potential tumors, and focal cortical dysplasia. Neuroradiologists independently described AE in 37 of 63 mTLE patients.Conclusions: mTLE‐AE has no specific clinical profile compared to non‐lesional mTLE and features diverse underlying pathologies. Volumetric detection appears more conservative than conventional qualitative visual analysis, but may miss cases of subtle AE. Combining automated volumetry with visual assessment may improve AE detection.
- 16 July 2024
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 30 (7) , e2013-e2023
Consultation Requests and Satisfaction with a Telehealth Network for Epilepsy: Longitudinal Analysis of the Epilepsy Network Hessen Evaluation
Background: Telemedicine improves access to specialized medical expertise, as required for paroxysmal disorders. The Epilepsy Network Hessen Evaluation (ENHE) is a pilot cross-sectoral teleconsultation network connecting primary neurologists and pediatricians with epilepsy centers in Hessen, a federal German state. Methods: We prospectively and longitudinally evaluated telehealthcare in the ENHE. Participating physicians rated each consultation for satisfaction and impact on further management. The survey was administered at each consultation and 3 months later. Results: We analyzed 129 consultations involving 114 adult and pediatric patients. Their mean age was 34 years (standard deviation: 26, range: 0.1–91 years), 48% were female, and 34% were children and adolescents. The most common consultation requests were co-evaluation of an electroencephalogram (electroencephalogram [EEG]; 76%) and therapeutic (33%) and differential diagnosis (24%) concerns. Physicians transmitted one paraclinical examination on average (range: 1–4), predominantly EEG (85%), followed by magnetic resonance imaging (17%) and written records (9%). Response rates were 72% for the initial and 67% for the follow-up survey. Across respondents, 99% ( n = 92) were satisfied with the ENHE. Overall, 80% of the consultations contributed to the diagnosis, and 90% were considered helpful for treatment, influencing it in 71% of cases. Seizure frequency had decreased more often (96%) than increased (4%) at 3 months. The initial diagnosis was confirmed in 78% of patients. Discussion: In this pilot teleconsultation network for paroxysmal disorders, diagnostic and therapeutic advice was perceived as helpful. Clinical outcomes were largely positive, suggesting tele-epileptology is viable for paroxysmal (seizure) disorders.
- 16 July 2024
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 30 (7) , e2013-e2023
Consultation Requests and Satisfaction with a Telehealth Network for Epilepsy: Longitudinal Analysis of the Epilepsy Network Hessen Evaluation
Background: Telemedicine improves access to specialized medical expertise, as required for paroxysmal disorders. The Epilepsy Network Hessen Evaluation (ENHE) is a pilot cross-sectoral teleconsultation network connecting primary neurologists and pediatricians with epilepsy centers in Hessen, a federal German state. Methods: We prospectively and longitudinally evaluated telehealthcare in the ENHE. Participating physicians rated each consultation for satisfaction and impact on further management. The survey was administered at each consultation and 3 months later. Results: We analyzed 129 consultations involving 114 adult and pediatric patients. Their mean age was 34 years (standard deviation: 26, range: 0.1–91 years), 48% were female, and 34% were children and adolescents. The most common consultation requests were co-evaluation of an electroencephalogram (electroencephalogram [EEG]; 76%) and therapeutic (33%) and differential diagnosis (24%) concerns. Physicians transmitted one paraclinical examination on average (range: 1–4), predominantly EEG (85%), followed by magnetic resonance imaging (17%) and written records (9%). Response rates were 72% for the initial and 67% for the follow-up survey. Across respondents, 99% ( n = 92) were satisfied with the ENHE. Overall, 80% of the consultations contributed to the diagnosis, and 90% were considered helpful for treatment, influencing it in 71% of cases. Seizure frequency had decreased more often (96%) than increased (4%) at 3 months. The initial diagnosis was confirmed in 78% of patients. Discussion: In this pilot teleconsultation network for paroxysmal disorders, diagnostic and therapeutic advice was perceived as helpful. Clinical outcomes were largely positive, suggesting tele-epileptology is viable for paroxysmal (seizure) disorders.
- Open Access
- 30 April 2024
- Published by Wiley in Epilepsia Open
- Vol. 9 (3) , 1021-1033
A multicenter randomized controlled feasibility trial of a digital self‐management intervention for adults with epilepsy
Objective: Self‐management interventions may enhance health‐related quality of life (HRQoL) in epilepsy. However, several barriers often impair their implementation in the real world. Digital interventions may help to overcome some of these barriers. Considering this, the Helpilepsy Plus Prototype was developed as a prototype smartphone‐delivered self‐care treatment program for adults with epilepsy.Methods: The 12‐week Helpilepsy Plus Prototype was evaluated through a randomized controlled feasibility trial with a waiting‐list control (WLC) group. Outcome measurement at baseline and at 12 weeks assessed adherence to the prototype intervention and changes in epilepsy‐related outcomes. The primary endpoint was patient autonomy measured with EASE, and secondary endpoints included HRQoL measured with QOLIE‐31, health literacy measured with HLQ, anxiety, and depression symptoms measured with HADS. Semi‐structured interviews were conducted with a heterogeneous sample of participants to assess user‐friendliness and usefulness. The prototype program was delivered through the Neuroventis Platform (Neuroventis, BV, Overijse, Belgium), a certified medical device (under EU/MDD Class I, and EU/MDR grace period).Results: Ninety‐two patients were included (46 in the intervention group, 46 in WLC). Most participants (63%, 58/92 women, median age 30 years) had pharmacoresistant epilepsy (61%, 56/92). Only 22% of participants (10/46) in the intervention group completed at least half of all intervention sessions. No significant differences between the intervention group and WLC were observed. Although there was a larger proportion of patients in the intervention group with meaningful improvements in HRQoL compared to WLC (19/46 versus 11/46), the difference was not significant (p = 0.119). Qualitative feedback showed that participants would appreciate more personalization, such as adaptation of the content to their current epilepsy knowledge level, a more interactive interface, shorter text sections, and interaction through reminders and notifications.Significance: Digital interventions should allow sufficient scope for personalization and interaction to increase patient engagement and enable benefits from self‐care apps. Feedback loops allow the participatory development of tailored interventions.Plain Language Summary: In this study, we investigated the effectiveness of an app‐based self‐help intervention. Study participants were either randomly assigned to a group that had access to the app or a group that received access to the app after the end of the study. Although a larger proportion of participants in the intervention group showed a relevant improvement in quality of life, the difference between the two groups was not statistically significant. Less than one‐fifth of participants in the intervention group attended at least half of all intervention sessions; patient feedback showed that patients required more personalization and interactive options.
- 30 April 2024
- Published by Wiley in Epilepsia Open
- Vol. 9 (3) , 1021-1033
Open AccessA multicenter randomized controlled feasibility trial of a digital self‐management intervention for adults with epilepsy
Objective: Self‐management interventions may enhance health‐related quality of life (HRQoL) in epilepsy. However, several barriers often impair their implementation in the real world. Digital interventions may help to overcome some of these barriers. Considering this, the Helpilepsy Plus Prototype was developed as a prototype smartphone‐delivered self‐care treatment program for adults with epilepsy.Methods: The 12‐week Helpilepsy Plus Prototype was evaluated through a randomized controlled feasibility trial with a waiting‐list control (WLC) group. Outcome measurement at baseline and at 12 weeks assessed adherence to the prototype intervention and changes in epilepsy‐related outcomes. The primary endpoint was patient autonomy measured with EASE, and secondary endpoints included HRQoL measured with QOLIE‐31, health literacy measured with HLQ, anxiety, and depression symptoms measured with HADS. Semi‐structured interviews were conducted with a heterogeneous sample of participants to assess user‐friendliness and usefulness. The prototype program was delivered through the Neuroventis Platform (Neuroventis, BV, Overijse, Belgium), a certified medical device (under EU/MDD Class I, and EU/MDR grace period).Results: Ninety‐two patients were included (46 in the intervention group, 46 in WLC). Most participants (63%, 58/92 women, median age 30 years) had pharmacoresistant epilepsy (61%, 56/92). Only 22% of participants (10/46) in the intervention group completed at least half of all intervention sessions. No significant differences between the intervention group and WLC were observed. Although there was a larger proportion of patients in the intervention group with meaningful improvements in HRQoL compared to WLC (19/46 versus 11/46), the difference was not significant (p = 0.119). Qualitative feedback showed that participants would appreciate more personalization, such as adaptation of the content to their current epilepsy knowledge level, a more interactive interface, shorter text sections, and interaction through reminders and notifications.Significance: Digital interventions should allow sufficient scope for personalization and interaction to increase patient engagement and enable benefits from self‐care apps. Feedback loops allow the participatory development of tailored interventions.Plain Language Summary: In this study, we investigated the effectiveness of an app‐based self‐help intervention. Study participants were either randomly assigned to a group that had access to the app or a group that received access to the app after the end of the study. Although a larger proportion of participants in the intervention group showed a relevant improvement in quality of life, the difference between the two groups was not statistically significant. Less than one‐fifth of participants in the intervention group attended at least half of all intervention sessions; patient feedback showed that patients required more personalization and interactive options.
- Open Access
- 4 June 2023
- Published by Springer Nature in CNS Drugs
- Vol. 37 (6) , 531-544
Adverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy
Background Antiseizure medication (ASM) as monotherapy or in combination is the treatment of choice for most patients with epilepsy. Therefore, knowledge about the typical adverse events (AEs) for ASMs and other coadministered drugs (CDs) is essential for practitioners and patients. Due to frequent polypharmacy, it is often difficult to clinically assess the AE profiles of ASMs and differentiate the influence of CDs. Objective This retrospective analysis aimed to determine typical AE profiles for ASMs and assess the impact of CDs on AEs in clinical practice. Methods The Liverpool AE Profile (LAEP) and its domains were used to identify the AE profiles of ASMs based on data from a large German multicenter study (Epi2020). Following established classifications, drugs were grouped according to their mode of action (ASMs) or clinical indication (CDs). Bivariate correlation, multivariate ordinal regression (MORA), and artificial neural network (ANNA) analyses were performed. Bivariate correlation with Fisher’s z-transformation was used to compare the correlation strength of LAEP with the Hospital Anxiety and Depression Scale (HADS) and Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) to avoid LAEP bias in the context of antidepressant therapy. Results Data from 486 patients were analyzed. The AE profiles of ASM categories and single ASMs matched those reported in the literature. Synaptic vesicle glycoprotein 2A (SV2A) and voltage-gated sodium channel (VGSC) modulators had favorable AE profiles, while brivaracetam was superior to levetiracetam regarding psychobehavioral AEs. MORA revealed that, in addition to seizure frequency, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) modulators and antidepressants were the only independent predictors of high LAEP values. After Fisher’s z-transformation, correlations were significantly lower between LAEP and antidepressants than between LAEP and HADS or NDDI-E. Therefore, a bias in the results toward over interpreting the impact of antidepressants on LAEP was presumed. In the ANNA, perampanel, zonisamide, topiramate, and valproic acid were important nodes in the network, while VGSC and SV2A modulators had low relevance for predicting relevant AEs. Similarly, cardiovascular agents, analgesics, and antipsychotics were important CDs in the ANNA model. Conclusion ASMs have characteristic AE profiles that are highly reproducible and must be considered in therapeutic decision-making. Therapy using perampanel as an AMPA modulator should be considered cautiously due to its relatively high AE profile. Drugs acting via VGSCs and SV2A receptors are significantly better tolerated than other ASM categories or substances (e.g., topiramate, zonisamide, and valproate). Switching to brivaracetam is advisable in patients with psychobehavioral AEs who take levetiracetam. Because CDs frequently pharmacokinetically interact with ASMs, the cumulative AE profile must be considered. Trial registration DRKS00022024, U1111-1252-5331.
- 4 June 2023
- Published by Springer Nature in CNS Drugs
- Vol. 37 (6) , 531-544
Open AccessAdverse Event Profiles of Antiseizure Medications and the Impact of Coadministration on Drug Tolerability in Adults with Epilepsy
Background Antiseizure medication (ASM) as monotherapy or in combination is the treatment of choice for most patients with epilepsy. Therefore, knowledge about the typical adverse events (AEs) for ASMs and other coadministered drugs (CDs) is essential for practitioners and patients. Due to frequent polypharmacy, it is often difficult to clinically assess the AE profiles of ASMs and differentiate the influence of CDs. Objective This retrospective analysis aimed to determine typical AE profiles for ASMs and assess the impact of CDs on AEs in clinical practice. Methods The Liverpool AE Profile (LAEP) and its domains were used to identify the AE profiles of ASMs based on data from a large German multicenter study (Epi2020). Following established classifications, drugs were grouped according to their mode of action (ASMs) or clinical indication (CDs). Bivariate correlation, multivariate ordinal regression (MORA), and artificial neural network (ANNA) analyses were performed. Bivariate correlation with Fisher’s z-transformation was used to compare the correlation strength of LAEP with the Hospital Anxiety and Depression Scale (HADS) and Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) to avoid LAEP bias in the context of antidepressant therapy. Results Data from 486 patients were analyzed. The AE profiles of ASM categories and single ASMs matched those reported in the literature. Synaptic vesicle glycoprotein 2A (SV2A) and voltage-gated sodium channel (VGSC) modulators had favorable AE profiles, while brivaracetam was superior to levetiracetam regarding psychobehavioral AEs. MORA revealed that, in addition to seizure frequency, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) modulators and antidepressants were the only independent predictors of high LAEP values. After Fisher’s z-transformation, correlations were significantly lower between LAEP and antidepressants than between LAEP and HADS or NDDI-E. Therefore, a bias in the results toward over interpreting the impact of antidepressants on LAEP was presumed. In the ANNA, perampanel, zonisamide, topiramate, and valproic acid were important nodes in the network, while VGSC and SV2A modulators had low relevance for predicting relevant AEs. Similarly, cardiovascular agents, analgesics, and antipsychotics were important CDs in the ANNA model. Conclusion ASMs have characteristic AE profiles that are highly reproducible and must be considered in therapeutic decision-making. Therapy using perampanel as an AMPA modulator should be considered cautiously due to its relatively high AE profile. Drugs acting via VGSCs and SV2A receptors are significantly better tolerated than other ASM categories or substances (e.g., topiramate, zonisamide, and valproate). Switching to brivaracetam is advisable in patients with psychobehavioral AEs who take levetiracetam. Because CDs frequently pharmacokinetically interact with ASMs, the cumulative AE profile must be considered. Trial registration DRKS00022024, U1111-1252-5331.
- Open Access
- 11 May 2023
- Published by Springer Nature in Clinical Epileptology
- Vol. 36 (3) , 217-223
Auswirkung der DRG-Abrechnung auf die Krankenhausverweildauer bei Patienten mit Epilepsie
Zusammenfassung Hintergrund Die Einführung der auf Fallpauschalen (DRG) basierten Abrechnung stationärer Krankenhausleistungen in Deutschland im Jahr 2003 hat die Patientenversorgung nachhaltig verändert. Ziel der Arbeit Ziel dieser Arbeit ist es, die Veränderung der Krankenhausverweildauer sowie die Häufigkeit stationärer Behandlungen bei Patienten mit Epilepsie zwischen den Jahren 2000 und 2020 zu erfassen und zu analysieren. Material und Methoden Mittels Zeitreihenanalyse (Interrupted Time Series Analysis [ITSA]) wurden Daten des Statistischen Bundesamtes zu Fallzahlen und Krankenhausverweildauer von Patienten mit Epilepsie in Deutschland statistisch auf signifikante Trendänderungen und deren Zeitpunkt untersucht. Ergebnisse Trotz eines fehlenden signifikanten Trends auf die mittlere Krankenhausverweildauer im Allgemeinen konnte ein signifikanter Trendwechsel in Bezug auf den Anteil unterschiedlicher Verweildauern von Patienten mit einer Tendenz zu vermehrt kürzeren Krankenhausbehandlungen nachgewiesen werden. Alle berechneten Änderungspunkte waren mit der DRG-Einführung zeitlich assoziiert. Für die weiterhin überwiegend mittels Tagessätzen abgerechneten stationären Rehabilitationsleistungen ließen sich diese Ergebnisse nicht reproduzieren. Zudem zeigte sich ein Anstieg stationär erbrachter spezialisierter epileptologischer Leistungen, insbesondere des Video-EEG-Monitorings. Diskussion Die Einführung der DRG-basierten Abrechnung stationärer Krankenhausfälle hat zu einer nachweisbaren, signifikanten Zunahme von kürzeren sowie zu einer Abnahme längerer stationärer Behandlungen geführt. Ob und inwiefern dies auch zu einer schlechteren Behandlung geführt hat, ist aus den für diese Studie verwendeten Daten nicht abzuleiten, sollte jedoch weitergehend analysiert werden.
- 11 May 2023
- Published by Springer Nature in Clinical Epileptology
- Vol. 36 (3) , 217-223
Open AccessAuswirkung der DRG-Abrechnung auf die Krankenhausverweildauer bei Patienten mit Epilepsie
Zusammenfassung Hintergrund Die Einführung der auf Fallpauschalen (DRG) basierten Abrechnung stationärer Krankenhausleistungen in Deutschland im Jahr 2003 hat die Patientenversorgung nachhaltig verändert. Ziel der Arbeit Ziel dieser Arbeit ist es, die Veränderung der Krankenhausverweildauer sowie die Häufigkeit stationärer Behandlungen bei Patienten mit Epilepsie zwischen den Jahren 2000 und 2020 zu erfassen und zu analysieren. Material und Methoden Mittels Zeitreihenanalyse (Interrupted Time Series Analysis [ITSA]) wurden Daten des Statistischen Bundesamtes zu Fallzahlen und Krankenhausverweildauer von Patienten mit Epilepsie in Deutschland statistisch auf signifikante Trendänderungen und deren Zeitpunkt untersucht. Ergebnisse Trotz eines fehlenden signifikanten Trends auf die mittlere Krankenhausverweildauer im Allgemeinen konnte ein signifikanter Trendwechsel in Bezug auf den Anteil unterschiedlicher Verweildauern von Patienten mit einer Tendenz zu vermehrt kürzeren Krankenhausbehandlungen nachgewiesen werden. Alle berechneten Änderungspunkte waren mit der DRG-Einführung zeitlich assoziiert. Für die weiterhin überwiegend mittels Tagessätzen abgerechneten stationären Rehabilitationsleistungen ließen sich diese Ergebnisse nicht reproduzieren. Zudem zeigte sich ein Anstieg stationär erbrachter spezialisierter epileptologischer Leistungen, insbesondere des Video-EEG-Monitorings. Diskussion Die Einführung der DRG-basierten Abrechnung stationärer Krankenhausfälle hat zu einer nachweisbaren, signifikanten Zunahme von kürzeren sowie zu einer Abnahme längerer stationärer Behandlungen geführt. Ob und inwiefern dies auch zu einer schlechteren Behandlung geführt hat, ist aus den für diese Studie verwendeten Daten nicht abzuleiten, sollte jedoch weitergehend analysiert werden.
- 1 April 2023
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 29 (4) , 540-550
Use of Health-Related Apps and Telehealth in Adults with Epilepsy in Germany: A Multicenter Cohort Study
Background:Telehealth can improve the treatment of chronic disorders, such as epilepsy. Telehealth prevalence and use increased during the coronavirus disease 2019 (COVID-19) pandemic. However, familiarity with and use of telehealth and health-related mobile applications (apps) by persons with epilepsy remain unknown. Methods:We investigated telehealth use, demographics, and clinical variables within the multicenter Epi2020 cross-sectional study. Between October and December 2020, adults with epilepsy completed a validated questionnaire, including individual questions regarding knowledge and use of apps and telehealth. Results:Of 476 included individuals (58.2% women; mean age 40.2 ± 15.4 years), 41.6% reported using health-related apps. Health apps were used more frequently (pedometer 32.1%, exercise app 17.6%) than medical apps (health insurance 15.1%, menstrual apps 12.2%) or apps designed for epilepsy (medication reminders 10.3%, seizure calendars 4.6%). Few used seizure detectors (i.e., apps as medical devices 1.9%) or mobile health devices (fitness bracelet 11.3%). A majority (60.9%) had heard the term telehealth, 78.6% of whom had a positive view. However, only 28.6% had a concrete idea of telehealth, and only 16.6% reported personal experience with telehealth. A majority (55%) would attend a teleconsultation follow-up, and 41.2% would in a medical emergency. Data privacy and availability were considered equally important by 50.8%, 21.8% considered data privacy more important, and 20.2% considered data availability more important. Current health-related app use was independently associated with younger age (p = 0.003), higher education (p < 0.001), and subjective COVID-19-related challenges (p = 0.002). Persistent seizure occurrence (vs. seizure freedom ≥12 months) did not affect willingness to use teleconsultations on multivariable logistic regression analysis. Conclusions:Despite positive telehealth views, few persons with epilepsy in Germany are familiar with specific apps or services. Socioeconomic factors influence telehealth use more than baseline epilepsy characteristics. Telehealth education and services should target socioeconomically disadvantaged individuals to reduce the digital care gap. German Clinical Trials Register (DRKS00022024; Universal Trial Number: U1111-1252-5331).
- 1 April 2023
- Published by SAGE Publications in Telemedicine and e-Health
- Vol. 29 (4) , 540-550
Use of Health-Related Apps and Telehealth in Adults with Epilepsy in Germany: A Multicenter Cohort Study
Background:Telehealth can improve the treatment of chronic disorders, such as epilepsy. Telehealth prevalence and use increased during the coronavirus disease 2019 (COVID-19) pandemic. However, familiarity with and use of telehealth and health-related mobile applications (apps) by persons with epilepsy remain unknown. Methods:We investigated telehealth use, demographics, and clinical variables within the multicenter Epi2020 cross-sectional study. Between October and December 2020, adults with epilepsy completed a validated questionnaire, including individual questions regarding knowledge and use of apps and telehealth. Results:Of 476 included individuals (58.2% women; mean age 40.2 ± 15.4 years), 41.6% reported using health-related apps. Health apps were used more frequently (pedometer 32.1%, exercise app 17.6%) than medical apps (health insurance 15.1%, menstrual apps 12.2%) or apps designed for epilepsy (medication reminders 10.3%, seizure calendars 4.6%). Few used seizure detectors (i.e., apps as medical devices 1.9%) or mobile health devices (fitness bracelet 11.3%). A majority (60.9%) had heard the term telehealth, 78.6% of whom had a positive view. However, only 28.6% had a concrete idea of telehealth, and only 16.6% reported personal experience with telehealth. A majority (55%) would attend a teleconsultation follow-up, and 41.2% would in a medical emergency. Data privacy and availability were considered equally important by 50.8%, 21.8% considered data privacy more important, and 20.2% considered data availability more important. Current health-related app use was independently associated with younger age (p = 0.003), higher education (p < 0.001), and subjective COVID-19-related challenges (p = 0.002). Persistent seizure occurrence (vs. seizure freedom ≥12 months) did not affect willingness to use teleconsultations on multivariable logistic regression analysis. Conclusions:Despite positive telehealth views, few persons with epilepsy in Germany are familiar with specific apps or services. Socioeconomic factors influence telehealth use more than baseline epilepsy characteristics. Telehealth education and services should target socioeconomically disadvantaged individuals to reduce the digital care gap. German Clinical Trials Register (DRKS00022024; Universal Trial Number: U1111-1252-5331).
- Open Access
Trends in resource utilization and cost of illness in patients with active epilepsy in Germany from 2003 to 2020
Objective: This study was undertaken to calculate epilepsy‐related direct, indirect, and total costs in adult patients with active epilepsy (ongoing unprovoked seizures) in Germany and to analyze cost components and dynamics compared to previous studies from 2003, 2008, and 2013. This analysis was part of the Epi2020 study.Methods: Direct and indirect costs related to epilepsy were calculated with a multicenter survey using an established and validated questionnaire with a bottom‐up design and human capital approach over a 3‐month period in late 2020. Epilepsy‐specific costs in the German health care sector from 2003, 2008, and 2013 were corrected for inflation to allow for a valid comparison.Results: Data on the disease‐specific costs for 253 patients in 2020 were analyzed. The mean total costs were calculated at €5551 (±€5805, median = €2611, range = €274–€21 667) per 3 months, comprising mean direct costs of €1861 (±€1905, median = €1276, range = €327–€13 158) and mean indirect costs of €3690 (±€5298, median = €0, range = €0–€11 925). The main direct cost components were hospitalization (42.4%), antiseizure medication (42.2%), and outpatient care (6.2%). Productivity losses due to early retirement (53.6%), part‐time work or unemployment (30.8%), and seizure‐related off‐days (15.6%) were the main reasons for indirect costs. However, compared to 2013, there was no significant increase of direct costs (−10.0%), and indirect costs significantly increased (p < .028, +35.1%), resulting in a significant increase in total epilepsy‐related costs (p < .047, +20.2%). Compared to the 2013 study population, a significant increase of cost of illness could be observed (p = .047).Significance: The present study shows that disease‐related costs in adult patients with active epilepsy increased from 2013 to 2020. As direct costs have remained constant, this increase is attributable to an increase in indirect costs. These findings highlight the impact of productivity loss caused by early retirement, unemployment, working time reduction, and seizure‐related days off.
Open AccessTrends in resource utilization and cost of illness in patients with active epilepsy in Germany from 2003 to 2020
Objective: This study was undertaken to calculate epilepsy‐related direct, indirect, and total costs in adult patients with active epilepsy (ongoing unprovoked seizures) in Germany and to analyze cost components and dynamics compared to previous studies from 2003, 2008, and 2013. This analysis was part of the Epi2020 study.Methods: Direct and indirect costs related to epilepsy were calculated with a multicenter survey using an established and validated questionnaire with a bottom‐up design and human capital approach over a 3‐month period in late 2020. Epilepsy‐specific costs in the German health care sector from 2003, 2008, and 2013 were corrected for inflation to allow for a valid comparison.Results: Data on the disease‐specific costs for 253 patients in 2020 were analyzed. The mean total costs were calculated at €5551 (±€5805, median = €2611, range = €274–€21 667) per 3 months, comprising mean direct costs of €1861 (±€1905, median = €1276, range = €327–€13 158) and mean indirect costs of €3690 (±€5298, median = €0, range = €0–€11 925). The main direct cost components were hospitalization (42.4%), antiseizure medication (42.2%), and outpatient care (6.2%). Productivity losses due to early retirement (53.6%), part‐time work or unemployment (30.8%), and seizure‐related off‐days (15.6%) were the main reasons for indirect costs. However, compared to 2013, there was no significant increase of direct costs (−10.0%), and indirect costs significantly increased (p < .028, +35.1%), resulting in a significant increase in total epilepsy‐related costs (p < .047, +20.2%). Compared to the 2013 study population, a significant increase of cost of illness could be observed (p = .047).Significance: The present study shows that disease‐related costs in adult patients with active epilepsy increased from 2013 to 2020. As direct costs have remained constant, this increase is attributable to an increase in indirect costs. These findings highlight the impact of productivity loss caused by early retirement, unemployment, working time reduction, and seizure‐related days off.
- Open Access
- 6 February 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (6) , 1836-1840
Local glucose metabolism is unaltered in reversible splenial lesion syndrome
Background Transient splenial oedema, also known as reversible splenial lesion syndrome (RESLES), is a rare magnetic resonance imaging (MRI) finding that presents as a round or ovoid focal oedema in the posterior corpus callosum, associated with a wide range of clinical conditions. The aetiology of RESLES is not fully clear. Here, we investigated conflicting pathophysiological hypotheses by measuring local glucose metabolism in patients with RESLES. Methods We retrospectively analysed patients with RESLES after reductions in antiseizure medications during in-hospital video electroencephalography (VEEG)-monitoring. We measured local glucose uptake using positron emission tomography/computed tomography (PET/CT) and compared matched cohorts of patients with and without MRI evidence of RESLES using non-parametric tests. Results Local glucose metabolism in the splenium of 7 patients with RESLES was not significantly different from the glucose metabolism of the 7 patients in the matched cohort. This was true using both regular and normalised standardised glucose uptake value calculation methods (p = 0.902 and p = 0.535, respectively). Conclusion We found no evidence of local glucose hypometabolism in RESLES, which supports previous pathophysiological considerations that suggest that RESLES is an intercellular, intramyelinic oedema rather than a typical intracellular cytotoxic oedema, which is not reversible.
- 6 February 2022
- Published by Wiley in European Journal of Neurology
- Vol. 29 (6) , 1836-1840
Open AccessLocal glucose metabolism is unaltered in reversible splenial lesion syndrome
Background Transient splenial oedema, also known as reversible splenial lesion syndrome (RESLES), is a rare magnetic resonance imaging (MRI) finding that presents as a round or ovoid focal oedema in the posterior corpus callosum, associated with a wide range of clinical conditions. The aetiology of RESLES is not fully clear. Here, we investigated conflicting pathophysiological hypotheses by measuring local glucose metabolism in patients with RESLES. Methods We retrospectively analysed patients with RESLES after reductions in antiseizure medications during in-hospital video electroencephalography (VEEG)-monitoring. We measured local glucose uptake using positron emission tomography/computed tomography (PET/CT) and compared matched cohorts of patients with and without MRI evidence of RESLES using non-parametric tests. Results Local glucose metabolism in the splenium of 7 patients with RESLES was not significantly different from the glucose metabolism of the 7 patients in the matched cohort. This was true using both regular and normalised standardised glucose uptake value calculation methods (p = 0.902 and p = 0.535, respectively). Conclusion We found no evidence of local glucose hypometabolism in RESLES, which supports previous pathophysiological considerations that suggest that RESLES is an intercellular, intramyelinic oedema rather than a typical intracellular cytotoxic oedema, which is not reversible.